Over the past few years, the industry has observed a striking increase of interest in other therapeutic areas beyond neurology and oncology – namely in radiotherapy, gastroenterology, inflammation, fibrosis, and mitochondrial imaging. In addition to our vast experience running neurology and oncology studies for sponsors, Invicro has invested in advancing its offerings in other therapeutic areas to accommodate this growing demand. Invicro has performed many successful imaging and therapy studies by leveraging valuable expertise that can be applied to future drug development trials.

Contact us


We have experience with alpha (225Ac) and beta (177Lu) emitting isotopes for preclinical radiotherapy efficacy studies with the aim for clinical translation and specifically:


  • Radiochemistry method development
  • Radioactive cell binding and internalization studies
  • Tumor efficacy studies and toxicity assessment via urinalysis
  • Complete blood count (CBC)
  • Hematological analysis
  • Preclinical focal beam radiation


Gut imaging tools used by Invicro include:


  • Contrast-enhanced CT for gastrointestinal (GI) segmentation
  • Evaluation of 18F-FDG PET in the monitoring of inflammatory activity in Crohn’s Disease compared to MRI imaging and the correlation with clinicopathological markers of severity
  • [11C]PBR28 PET imaging in Crohns disease
  • Preclinical GI transit studies of a radiopaque capsule
  • Studies to assess gastric accommodation and emptying with SPECT as a translational tool for gut-brain axis research
  • Screening studies to assess colon wall thickness in DSS insulted animals using MR imaging and confirmed by histology
  • Capacity to perform simultaneous PET-MR imaging and RAMIRS scoring


Invicro has experience with various arthritis and inflammatory bowel disease (IBS) models across various animal species. PET imaging has been previously used as assessment metrics of disease onset and progression in arthritis models. For example:


  • Using 18F-FDG and 18F-NaF along with CT has been used to assess bone density, joint swelling, and surface roughness
  • Capacity to support clinical imaging in arthritis including Rheumatoid and Psoriatic


For more information, view our case studies below:

Lung Inflammation: Asthma


Invicro has access to various preclinical fibrosis models, such as bleomycin pulmonary fibrosis, kidney fibrosis and more. Previous fibrosis work at Invicro includes:


  • Work with the ligand [18F]IMAFIB for the integrin alphavbeta6, which is upregulated in some pathways of fibrosis and can be used for PET imaging studies
  • MicroCT imaging of fibrotic lungs and use of dense tissue values to differentiate fibrotic from non-fibrotic tissue
  • Ex vivo visualization of fluorescently-tagged antibodies targeting fibrotic markers utilizing three dimensional cryo-fluorescence imaging
  • Preclinical and clinical imaging support for NASH including, multi-parametric liver MR imaging, histology services, PET imaging and elastography


For more information, view our case studies below:

Lipid Quantification Tool Development Using Multi-Echo MRI